Ascentage Pharma Group International AAPG
Ascentage Pharma Group International (Nasdaq: AAPG) is an oncology drug developer. Its lead program, Olverembatinib (HQP1351), is in Phase 3 for Ph+ ALL (POLARIS-1), previously treated CML-CP (POLARIS-2), SDH-deficient GIST (POLARIS-3). Its next catalyst on record is Lisaftoclax: Pursue inclusion in China NRDL (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Lisaftoclax — Pursue inclusion in China NRDL (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Olverembatinib (HQP1351) | Ph+ ALL, CML-CP, SDH-deficient GIST (global registrational Phase 3; NMPA-approved in CML in China) | small molecule | Phase 3 |
| Lisaftoclax (APG-2575) | CLL/SLL (GLORA, GLORA-2), AML (GLORA-3), HR-MDS (GLORA-4); NMPA-approved in R/R CLL/SLL in China | small molecule | Phase 3 |
| Lisaftoclax (APG-2575) | Multiple myeloma, AML/MDS combinations (Ph1b/2) | small molecule | Phase 2 |
| Alrizomadlin (APG-115) | MDM2-p53 inhibitor, solid/heme tumors | small molecule | Phase 2 |
| Pelcitoclax (APG-1252) | Bcl-2/Bcl-xL inhibitor | small molecule | Phase 1 |
| APG-2449 | FAK/ALK/ROS1 inhibitor | small molecule | Phase 1 |
| APG-5918 | EED inhibitor (PRC2) | small molecule | Phase 1 |
| APG-3288 | R/R B-cell malignancies (BTK degrader) | small molecule | Phase 1 |
Recent results and decisions
- Jun 14, 2026positive Phase Ib (n=22): 44.4% (4/9) of ASXL1-mutant patients responded, 22.2% achieved MMR.
After olverembatinib treatment, 44.4% (4/9) of patients with ASXL1 mutations achieved clinical responses, including 22.2% (2/9) who achieved MMR, one of whom achieved MR4.5.
Filing - May 31, 2026positive Phase Ib at ASCO: 91% (10/11) CR/CRi, 67% PCR negativity, 80% (8/10) flow MRD negativity; manageable safety.
A total of 91% (10/11) of patients achieved complete response (CR) or complete response with incomplete hematologic recovery (CRi).
Filing - Feb 5, 2026n/a China CDE cleared the IND for BTK degrader APG-3288 (ex-US regulatory action); Phase I planned.
announced that its novel next-generation Bruton's tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance from the China Center for Drug Evaluation (CDE)
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.